Fig. 3

FASN inhibition drives membrane lipid poly-unsaturation. a Relative abundance of indicated lipid species in Mel006 tumors harvested at T0 (n = 6), T4 (n = 4) and Tres (n = 5). One-way ANOVA with Tukey’s multiple comparisons. b Relative abundance of indicated lipid species in Mel006 tumors following MAPKi and TVB-3664 treatment (n = 3). One-way ANOVA with Tukey’s multiple comparisons. c Phospholipidomics of PC, PE, PI, PS and PG species in D10 BMR cells (n = 3) treated with DT, TVB-3664 or DT + TVB-3664 in combination with exposure with oleate, palmitate or a 1:1 mixture of PUFA (linoleate and linolenate). Two-way ANOVA with Tukey’s multiple comparisons. d Real time cell growth analysis of D10 BMR cells (n = 3) with supplementation of exogenous palmitate, oleate, or PUFA at 300 h. Two-way ANOVA with Tukey’s multiple comparisons. Data represent mean ± SEM of biologically independent samples